For US Healthcare Professionals
For US Healthcare Professionals
IN ADULTS WITH ACTIVE PSORIATIC ARTHRITIS (PsA)
DISCOVER 2: ACR20, ACR50, AND ACR70 RESPONSES AT WEEK 24 (NONRESPONDER IMPUTATION [NRI])*†
ACR50 response and ACR70 response at Week 24 were not part of the sequential testing procedure but were prespecified to be tested upon achieving statistical significance for ACR20 response.
DISCOVER 1: ACR20, ACR50, AND ACR70 RESPONSES AT WEEK 24 (NRI)*†
ACR50 response and ACR70 response at Week 24 were not part of the sequential testing procedure but were prespecified to be tested upon achieving statistical significance for ACR20 response.
References: 1. Mease PJ, Rahman P, Gottlieb AB, et al. Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER 2): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2020;20(30263):1-11. 2. Deodhar A, Helliwell PS, Boehncke WH, et al. Guselkumab in patients with active psoriatic arthritis who were biologic-naïve or had previously received TNFα inhibitor treatment (DISCOVER 1): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2020;20(30265):1-11.
DISCOVER 2: ACR20 RESPONSE THROUGH WEEK 52
52-WEEK DATA
DISCOVER 1: ACR20 RESPONSE AT WEEK 24 AND WEEK 52
References: 1. Mease PJ, Rahman P, Gottlieb AB, et al. Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER 2): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2020;20(30263):1-11. 2. Data on File. Janssen Biotech, Inc. 3. Deodhar A, Helliwell PS, Boehncke WH, et al. Guselkumab in patients with active psoriatic arthritis who were biologic-naïve or had previously received TNFα inhibitor treatment (DISCOVER 1): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2020;20(30265):1-11.
DISCOVER 1: ACR20 RESPONSE RATES—NO PRIOR ANTI-TNFα EXPOSURE
ACR20 response by prior anti-TNFα exposure was not adjusted for multiplicity. Therefore, statistical significance has not been established.
DISCOVER 1: ACR20 RESPONSE RATES—PRIOR ANTI-TNFα EXPOSURE
ACR20 response by prior anti-TNFα exposure was not adjusted for multiplicity. Therefore, statistical significance has not been established.
References: 1. Data on File. Janssen Biotech, Inc. 2. Deodhar A, Helliwell PS, Boehncke WH, et al. Guselkumab in patients with active psoriatic arthritis who were biologic-naïve or had previously received TNFα inhibitor treatment (DISCOVER 1): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2020;20(30265):1-11.
DISCOVER 2: ACR20, ACR50, AND ACR70 RESPONSES AT WEEK 24 (NONRESPONDER IMPUTATION [NRI])*†
ACR50 response and ACR70 response at Week 24 were not part of the sequential testing procedure but were prespecified to be tested upon achieving statistical significance for ACR20 response.
DISCOVER 1: ACR20, ACR50, AND ACR70 RESPONSES AT WEEK 24 (NRI)*†
ACR50 response and ACR70 response at Week 24 were not part of the sequential testing procedure but were prespecified to be tested upon achieving statistical significance for ACR20 response.
References: 1. Mease PJ, Rahman P, Gottlieb AB, et al. Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER 2): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2020;20(30263):1-11. 2. Deodhar A, Helliwell PS, Boehncke WH, et al. Guselkumab in patients with active psoriatic arthritis who were biologic-naïve or had previously received TNFα inhibitor treatment (DISCOVER 1): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2020;20(30265):1-11.
DISCOVER 2: ACR20 RESPONSE THROUGH WEEK 52
52-WEEK DATA
DISCOVER 1: ACR20 RESPONSE AT WEEK 24 AND WEEK 52
References: 1. Mease PJ, Rahman P, Gottlieb AB, et al. Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER 2): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2020;20(30263):1-11. 2. Data on File. Janssen Biotech, Inc. 3. Deodhar A, Helliwell PS, Boehncke WH, et al. Guselkumab in patients with active psoriatic arthritis who were biologic-naïve or had previously received TNFα inhibitor treatment (DISCOVER 1): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2020;20(30265):1-11.
DISCOVER 1: ACR20 RESPONSE RATES—NO PRIOR ANTI-TNFα EXPOSURE
ACR20 response by prior anti-TNFα exposure was not adjusted for multiplicity. Therefore, statistical significance has not been established.
DISCOVER 1: ACR20 RESPONSE RATES—PRIOR ANTI-TNFα EXPOSURE
ACR20 response by prior anti-TNFα exposure was not adjusted for multiplicity. Therefore, statistical significance has not been established.
References: 1. Data on File. Janssen Biotech, Inc. 2. Deodhar A, Helliwell PS, Boehncke WH, et al. Guselkumab in patients with active psoriatic arthritis who were biologic-naïve or had previously received TNFα inhibitor treatment (DISCOVER 1): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2020;20(30265):1-11.